Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
09:08am, Tuesday, 25'th Nov 2025
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth Buying
08:37am, Tuesday, 25'th Nov 2025
Novo Nordisk A/S shares fell after phase 3 trials showed semaglutide did not slow Alzheimer's progression, though the trials were a longshot due to low optimism. NVO remains fundamentally strong, with
Novo Nordisk: The Fundamental Story Remains Strong, So I Bought More
08:24am, Tuesday, 25'th Nov 2025
Novo Nordisk faces negative headlines, but recent share price weakness presents a compelling long-term buying opportunity. NVO's failed Alzheimer's trial, restructuring, and price cuts have pressured
Novo Nordisk's weight-loss-drug trial provides rare good news in a rocky year
08:04am, Tuesday, 25'th Nov 2025
Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development.
First Look: Alphabet nears $4T as Google chip talks jolt Nvidia
07:38am, Tuesday, 25'th Nov 2025
Stock News Wall Street jumps on rate-cut hopes: Alphabet (GOOGL) and Tesla (TSLA) led a tech rebound as odds of a December Fed cut climbed, lifting the Nasdaq 2
Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial
07:05am, Tuesday, 25'th Nov 2025
The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
06:34am, Tuesday, 25'th Nov 2025
Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
06:24am, Tuesday, 25'th Nov 2025
Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. This marks the first evalua
Here's why the Novo Nordisk stock has crashed by 70%
03:38am, Tuesday, 25'th Nov 2025
Novo Nordisk stock price has suffered a harsh reversal this year as the company's woes have escalated. It plunged to a low of DKK 267.50 on Monday, down by over 70% from its highest point in 2024, wit
Novo Nordisk A/S (NYSE:NVO) Shares Gap Down Following Analyst Downgrade
01:20am, Tuesday, 25'th Nov 2025
Novo Nordisk A/S (NYSE: NVO - Get Free Report) gapped down prior to trading on Monday after HSBC downgraded the stock from a buy rating to a hold rating. The stock had previously closed at $47.63, but
Why Novo Nordisk Stock Sank 5.6% Today
06:48pm, Monday, 24'th Nov 2025
Novo Nordisk's Phase II trial found that semaglutide did not slow Alzheimer's progression. The setback comes as competition heats up in the obesity and diabetes drug market.
Mizuho's Jared Holz talks Novo Nordisk falling on Alzheimer's trial
06:22pm, Monday, 24'th Nov 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk shares sliding on latest drug trial and how to treat the stock at its current lows.
Market Today: Alphabet rallies, Amazon's $50B AI push
05:35pm, Monday, 24'th Nov 2025
Guru Stock PicksElfun Trusts has made the following transactions:Reduce in MLM by 7.18%Sold out in KVUEAdd in TXN by 36.84%New position in AMDStock News Tech-le
There's still hope GLP-1 drugs could slow the second-biggest type of dementia
04:57pm, Monday, 24'th Nov 2025
Can GLP-1s treat vascular dementia? One study failed, but some researchers are holding out hope.
Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More
04:49pm, Monday, 24'th Nov 2025
Markets got into rally mode on Monday. News from a top maker of weight-loss drugs wasn't as positive as investors had hoped.
